For example, anti-tumor mAbs targeting the epidermal growth factor receptor (EGFR) can cause skin problems due to the expression of EGFR in skin cells.163,164 Meanwhile, immunogenicity refers to the development of anti-drug antibodies (ADAs) by the patient’s immune system in response to the therapeutic mAb. This evidence concerns the gene EGFR and neoplasm.